

CITATION REPORT

List of articles citing

Ophthalmologic safety of long-term hydroxychloroquine treatment

DOI: [10.1002/art.1780220805](https://doi.org/10.1002/art.1780220805)

Arthritis and Rheumatism, 1979, 22, 832-6.

Source: <https://exaly.com/paper-pdf/14078942/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
102	Steroids, gold, hydroxychloroquine. 1980 , 3, 320-4		2
101	The effect of fasting on plasma cyclic adenosine-3', 5'-monophosphate in rheumatoid arthritis. 1980 , 9, 229-33		7
100	Antirheumatic drugs: clinical pharmacology and therapeutic use. 1980 , 20, 453-84		20
99	Lupus erythematosus. 1981 , 4, 127-42		51
98	Pharmacotherapy of juvenile rheumatoid arthritis. 1981 , 28, 161-77		8
97	Treatment of chronic Lyme arthritis with hydroxychloroquine. <i>Arthritis and Rheumatism</i> , 1981 , 24, 1567-9		19
96	The place of antimalarials in rheumatology. 1981 , 40, 323-324		3
95	Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective. 1982 , 41 Suppl 1, 1-60		2
94	References. 1982 , 41, 54-60		1
93	Therapy of cutaneous lupus erythematosus. 1982 , 66, 795-805		11
92	Antimalarials in rheumatic diseases. 1982 , 12, 645-9		7
91	Antiprotozoal drugs. 1982 , 261-267		
90	Antimalarials and ophthalmologic safety. 1982 , 6, 19-23		39
89	Systemic lupus erythematosus: important considerations in the adolescent. 1982 , 2, 273-8		6
88	Ophthalmologic aspects of chloroquine and hydroxychloroquine therapy. 1983 , 22, 273-8		10
87	Antimalarial drugs for rheumatoid arthritis. 1983 , 75, 48-58		59
86	Hydroxychloroquine in the treatment of rheumatoid arthritis. 1983 , 75, 321-6		36

85	Pharmacologic actions of 4-aminoquinoline compounds. 1983 , 75, 5-10	115
84	Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. 1983 , 75, 25-34	107
83	Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. 1983 , 75, 35-9	135
82	Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. 1983 , 75, 40-5	204
81	Chapter 18. Disease Modifying Anti-Rheumatic Drugs. 1983 , 18, 171-179	4
80	Retinal Toxicity of Therapeutic Agents. 1983 , 2, 131-152	6
79	Adverse ocular reactions to drugs. 1983 , 59, 343-9	13
78	Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1984 , 27, 267-76	101
77	Disease-modifying antirheumatic drugs. 1985 , 5, 371-90	4
76	Hydroxychloroquine treatment and the eye. 1985 , 14, 171-4	15
75	Therapeutic approaches to the treatment of rheumatoid disease. 1986 , 70, 285-304	7
74	Retinopathy in systemic lupus erythematosus: relationship to disease activity. <i>Arthritis and Rheumatism</i> , 1986 , 29, 1152-6	66
73	Current management of juvenile arthritis. 1986 , 53, 617-24	
72	Antioxidant action of antimalarials. 1986 , 45, 244-8	40
71	Plasma hydroxychloroquine concentrations and efficacy in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1987 , 30, 567-71	38
70	Antimalarials in rheumatology: efficacy and safety. 1987 , 16, 206-21	69
69	Hydroxychloroquine in polymorphic light eruption: a controlled trial with drug and visual sensitivity monitoring. 1987 , 116, 379-86	74
68	The optimum management of arthropathies. 1988 , 36, 370-81	1

67	Rheumatologic causes of pain: rheumatoid arthritis. 1988 , 23, 57-8, 61, 65-6	
66	Misconceptions about antimalarials. 1989 , 28, 648-9	2
65	Ocular Effects of Systemic Drugs. 1989 , 801-842	2
64	Risk factors of second-line antirheumatic drugs in rheumatoid arthritis. 1990 , 19, 337-52	27
63	A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. 1991 , 324, 150-4	507
62	Systemic Therapeutic Agents and Retinal Toxicity. 1991 , 6, 45-64	1
61	Hydroxychloroquine: a guide to usage. 1992 , 3, 103-106	8
60	Antimalarial Agents and the Eye. 1992 , 10, 513-519	
59	Comparative efficacy and safety of advanced drug therapy in children with juvenile rheumatoid arthritis. 1993 , 23, 34-46	50
58	Antimalarials for children: indications, toxicities, and guidelines. 1993 , 28, 764-70	35
57	Control of Rheumatoid Disease as a Requisite for Successful Outcome of Rehabilitation. 1994 , 5, 663-684	1
56	A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis. 1994 , 11, 21-36	4
55	Update on pharmacotherapy of systemic lupus erythematosus. 1995 , 52, 2686-95	4
54	Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. 1995 , 17, 622-36	124
53	Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. 1996 , 18, 1080-92	84
52	Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. 1996 , 5, 237-41	98
51	Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data. 1997 , 36, 599-601	35
50	Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. 1997 , 19, 913-23	81

49	Royal College of Ophthalmologists guidelines: ocular toxicity and hydroxychloroquine. 1998 , 12 (Pt 6), 907-9	36
48	Long-term effectiveness of antimalarial drugs in rheumatic diseases. 1998 , 57, 582-7	72
47	Chloroquine retinopathy and secondary trauma. 2000 , 12, 161-165	1
46	Management of patients undergoing hydroxychloroquine (Plaquenil) therapy. 2000 , 83, 32-36	8
45	Combination therapy for autoimmune diseases: the rheumatoid arthritis model. 2001 , 23, 5-26	7
44	Avaliaço da toxicidade ocular por derivados da 4-aminoquinolona. 2002 , 65, 645-649	2
43	Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. 2002 , 133, 649-56	83
42	Polymorphic light eruption. 2003 , 16, 28-39	38
41	Lupus nephritis: a review of the current pharmacological treatments. 2004 , 5, 2263-77	3
40	Factors associated with chloroquine-induced retinopathy in rheumatic diseases. 2004 , 13, 119-24	28
39	Multifocal electroretinographic changes in patients receiving hydroxychloroquine therapy. 2005 , 140, 794-807	86
38	Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. 2006 , 112, 177-87	44
37	[Ocular toxicity due to 4-aminoquinoline derivatives]. 2007 , 70, 1046-51	8
36	Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration?. 2007 , 26, 1248-53	25
35	Central nervous system involvement in pediatric rheumatic diseases: current concepts in treatment. 2008 , 14, 1295-301	33
34	Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. 2010 , 94, 1637-42	27
33	PHARMACOLOGY AND DRUG THERAPY. 2011 , 71-126	18
32	Value of red targets and pattern deviation plots in visual field screening for hydroxychloroquine retinopathy. 2013 , 131, 476-80	17

31	Hydroxychloroquine and Chloroquine Retinopathy. 2014 ,	25
30	Anti-malarials: Are There Benefits Beyond Mild Disease?. 2016 , 2, 1-12	5
29	Pharmacology and Drug Therapy: Nonbiologic Therapies. 2016 , 140-160.e16	
28	Leading causes of methotrexate and antimalarial drugs discontinuation in Iranian patients with rheumatoid arthritis. 2016 , 38, 147-152	6
27	Short-term, high-dose hydroxychloroquine corneal toxicity. 2020 , 18, 100713	2
26	Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019. 2021 , 53, 117-134	26
25	Hydroxychloroquine and SARS-CoV-2 (COVID-19): An Old Problem and New Considerations in Ophthalmology. 2021 , 14, 78-81	
24	The Discovery of Drugs to Treat Arthritis: A Historical View. 1995 , 1-26	1
23	Juvenile Rheumatoid Arthritis. 1993 , 231-359	6
22	Juvenile Rheumatoid Arthritis. 1982 , 179-273	1
21	Medikamentöse Therapie. 1983 , 335-485	1
20	Prediction of the clinical efficacy of and intolerance to antirheumatic drug therapy. 1991 , 347-402	4
19	PHARMACOLOGY AND DRUG THERAPY. 2005 , 76-141	9
18	Antimalarial Therapy in SLE. 1982 , 8, 279-298	25
17	Chloroquine and Hydroxychloroquine in Rheumatological Therapy. 1980 , 6, 545-566	67
16	The Skin and the Eye. 1990 , 8, 297-311	2
15	ANTIMALARIAL AGENTS AND LUPUS. 1994 , 20, 243-263	96
14	Therapeutic Approaches for Ophthalmic Problems in Juvenile Rheumatoid Arthritis. 1989 , 15, 413-437	12

- 13 Evaluation of Hydroxychloroquine Retinopathy With Multifocal Electroretinography. **2003**, 34, 251-258 26
- 12 Combination therapy for autoimmune diseases: the rheumatoid arthritis model. **2002**, 5-26
- 11 Epidemiology of Hydroxychloroquine and Chloroquine Retinopathy. **2014**, 95-106
- 10 Drug-induced syndromes and drug toxicity. **1986**, 479-513
- 9 Rheumatoid arthritis. **1986**, 321-357
- 8 Antimalarial-induced ocular toxicity during the treatment of rheumatoid arthritis. **1987**, 201-208
- 7 Retinotoxic Agents and its Pathogenesis. **1988**, 133-159
- 6 Halcinonid. **1993**, 401-515
- 5 Ocular Manifestations of Pediatric Rheumatic Diseases. **2017**, 643-703
- 4 Drug therapy (3): Specific drugs. **1983**, 169-212
- 3 Antimalarials and Other Second-Line Drugs. **1983**, 159-164 0
- 2 Orthopedic surgery. *Arthritis and Rheumatism*, **1983**, 26, 359-436
- 1 Evaluation of hydroxychloroquine retinopathy with multifocal electroretinography. *Ophthalmic Surgery, Lasers and Imaging*, **2003**, 34, 251-8 11